Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00870987 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria
A Phase 1 study of Malaria, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 1
- Study location
NCT00870987 is a Phase 1 study of Malaria that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 82 participants, below the 255-participant average among 27 other Malaria trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00870987, a Phase 1 study of Malaria, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety and effectiveness of a new malaria vaccine, the DNA-Ad vaccine. The study is specifically looking at a vaccine regimen against Plasmodium falciparum, the most deadly form of malaria.
Conditions Studied
Interventions
- BIOLOGICAL DNA vaccine prime
- BIOLOGICAL adenovirus type 5 vaccine boost
Study Locations (1)
Maryland
- Clinical Trials Center, WRAIR - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2009-05 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00870987
The ClinicalTrials.gov registry entry for NCT00870987 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 27 other Malaria trials with a reported enrollment target (68% lower). The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malaria appearing as the primary indexed condition, and to 2 interventions - of which DNA vaccine prime is the first listed.
NCT00870987 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00870987 about?
NCT00870987 is a clinical study titled "Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria". The purpose of this study is to test the safety and effectiveness of a new malaria vaccine, the DNA-Ad vaccine. The study is specifically looking at a vaccine regimen against Plasmodium falciparum, the most deadly form of malaria.
What is the current status of trial NCT00870987?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2009-05. Estimated completion is 2015-07.
What conditions does trial NCT00870987 study?
This clinical trial studies the following conditions: Malaria.
What interventions are being tested in trial NCT00870987?
The interventions under investigation include: DNA vaccine prime (BIOLOGICAL), adenovirus type 5 vaccine boost (BIOLOGICAL).
Who is sponsoring clinical trial NCT00870987?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00870987 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral E1018 in Healthy Adult Participants
RECRUITING · Phase 1
-
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
RECRUITING · Phase 1
-
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
ACTIVE NOT RECRUITING · Phase 1
-
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
ACTIVE NOT RECRUITING · Phase 1
-
Trial to Evaluate CIS43LS in Healthy Adults
COMPLETED · Phase 1
-
Blood-Stage Plasmodium Vivax Cell Bank
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.